Free Trial
NASDAQ:GLSI

Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

Greenwich LifeSciences logo
$14.06 -0.33 (-2.29%)
(As of 11/11/2024 ET)

About Greenwich LifeSciences Stock (NASDAQ:GLSI)

Key Stats

Today's Range
$13.67
$14.67
50-Day Range
$12.90
$15.29
52-Week Range
$8.00
$21.44
Volume
17,172 shs
Average Volume
40,115 shs
Market Capitalization
$184.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.00
Consensus Rating
Buy

Company Overview

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Greenwich LifeSciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
31st Percentile Overall Score

GLSI MarketRank™: 

Greenwich LifeSciences scored higher than 31% of companies evaluated by MarketBeat, and ranked 806th out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Greenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Greenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Greenwich LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Greenwich LifeSciences are expected to decrease in the coming year, from ($0.81) to ($0.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Greenwich LifeSciences is -17.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Greenwich LifeSciences is -17.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Greenwich LifeSciences has a P/B Ratio of 27.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Greenwich LifeSciences' valuation and earnings.
  • Percentage of Shares Shorted

    8.47% of the float of Greenwich LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Greenwich LifeSciences has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Greenwich LifeSciences has recently increased by 1.11%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Greenwich LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Greenwich LifeSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.47% of the float of Greenwich LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Greenwich LifeSciences has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Greenwich LifeSciences has recently increased by 1.11%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Greenwich LifeSciences this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for GLSI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $33,025.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    52.86% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 4.16% of the stock of Greenwich LifeSciences is held by institutions.

  • Read more about Greenwich LifeSciences' insider trading history.
Receive GLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

GLSI Stock News Headlines

Election warning coming true…
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
Greenwich Lifesciences Inc (GLSI)
See More Headlines

GLSI Stock Analysis - Frequently Asked Questions

Greenwich LifeSciences' stock was trading at $10.52 on January 1st, 2024. Since then, GLSI shares have increased by 33.7% and is now trading at $14.06.
View the best growth stocks for 2024 here
.

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20).

Greenwich LifeSciences (GLSI) raised $7 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 1,300,000 shares at a price of $5.75 per share. Aegis Capital served as the underwriter for the IPO.

Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Greenwich LifeSciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/14/2024
Today
11/11/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GLSI
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.00
High Stock Price Target
$38.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+170.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-8,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.52 per share

Miscellaneous

Free Float
6,197,000
Market Cap
$184.89 million
Optionable
Not Optionable
Beta
1.62
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:GLSI) was last updated on 11/12/2024 by MarketBeat.com Staff
From Our Partners